METTL14 and neoplasm: In a recent study, the downexpression of METTL14 has been reported to act as an adverse prognosis factor for recurrence‐free survival of hepatocellular carcinoma and be associated with tumor metastasis in vitro and in vivo (Ma et al., 2017).